ATOSSA THERAPEUTICS, INC. — Director's Dealing 2023

Oct 16, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2023-10-06

Reporting Person: Rees Heather (SVP, Finance and Accounting)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.4800	2030-04-09	Common Stock (32500)		Direct
Stock Option (Right to Buy)	$3.1800	2030-07-03	Common Stock (23500)		Direct
Stock Option (Right to Buy)	$2.9000	2031-05-14	Common Stock (129700)		Direct
Stock Option (Right to Buy)	$3.1800	2031-08-11	Common Stock (100000)		Direct
Stock Option (Right to Buy)	$0.9300	2032-05-13	Common Stock (150000)		Direct
Stock Option (Right to Buy)	$0.9200	2033-06-12	Common Stock (226000)		Direct

Footnotes

F1: The options are fully vested.

F2: The options vest in equal quarterly installments over a period of two years from the grant date, May 13, 2022, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3: The options vest in equal quarterly installments over a period of two years from the grant date, June 12, 2023, subject to the Reporting Person's continued service to Issuer through each vesting date.